Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (11251)	8/16/1999 9:56:00 PM
From: RXGOLF	Read Replies (1) \| Respond to of 17367

I am afraid you will get your chance to buy on a dip very soon. Why would the numbers not be announced if they were favorable? If we would have had 6 deaths, do you not think that those numbers would have not been released? IMHO, XOMA is trying to buy time to add the appropriate window dressings to what has turned out to be a questionable product. IMO, if the numbers were good at all, I would stick them in everyones face(including the FDA), telling the world that we have a drug that CAN SAVE dying children!! If the numbers were good, that would make the FDA fast track, a faster track. Look at the time it took to approve the new protease inhibitor, nelfinavir. It took 2.7 months. I don't think they were holding back any numbers. Please don't take this post as offensive, never been anything but long on XOMA! Good luck to all, Greg

To: Bluegreen who wrote (11251)	8/16/1999 10:06:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

"Meeting with FDA to review Phase III meningococcemia trial data" This is how the release begins. Later we learn they are scheduling a meeting and we were told in the conference call that we could expect to hear something in October. It was also mentioned that the the FDA needs 4 weeks to review the data submitted. You are correct as have been other posters. XOMA has said they believe BPI was clinically effective in both mortality and morbidity. This is something raw mortality numbers would not have told us. Obviously fewer subjects receiving BPI died than in the placebo trial, and obviously fewer subjects suffered morbidity. enough fewer for XOMA to say it believed it was clinically effective. Expect we will have a meeting very soon with the FDA and of course I will be hoping the FDA does not need the full four weeks to review the data. We owe a vote of thanks to XOMA for including us in the conference call. It was probably also a wise decision to hold the call after the market had closed. I for one, needed more time and input from others to better understand the entire issue. So thanks to several other thoughtful posters on R.B., here and on Yahoo also.

To: Bluegreen who wrote (11251)	8/16/1999 10:33:00 PM
From: Edward Paule	Read Replies (2) \| Respond to of 17367

>>>> I still can't believe some think Xoma could say more than they did at this point in time! <<<< On what page, of what legal document does it say that Xoma cannot say anything specific until it talks to the FDA? I've had the unfortunate experience of being a member of several class action lawsuits. Each of these were biotech companies that tanked after disappointing news was released (Synergen, Centocor, Immunex, Chiron). Some of these later recovered; but that's irrelevant. All these lawsuits read the same. When did management "know" there was bad news, and when did they "tell" the public. When these dates aren't close together (days), that spells lawsuit. Members of the class become those that bought the stock in between the "know" and "tell" dates. Basically, anyone buying stock during that timeframe should have known the bad news but didn't because of management's failure to communicate it in a timely manner. If Xoma "knows" now and doesn't "tell" until October, and Xoma tanks as a result, then everyone who buys between tomorrow and October could very well be members of a class action lawsuit. I, of course, do not want to see this happen. So I'll ask again: What legal document states that Xoma can't tell now? - Ed